PharmGKB Pathway Peginterferon-α published in Pharmacogenetics and Genomics

The PharmGKB summary: peginterferon-α pathway has been published in the Pharmacogenetics and Genomics Journal. Peginterferon-α (pegylated interferon-α or PEG-IFN-α) is an antiviral drug used to treat chronic hepatitis C virus (HCV) infection. The PharmGKB review summarizes the pharmacokinetics and pharmacodynamics of peginterferon-α and also discusses genetic variations around the IFNL3 locus (formerly known as IL28B) affecting the viral clearance and clinical responses to peginterferon-α based therapy.

Find out more...

View interactive Peginterferon-α pathway on PharmGKB.

Read our new publication: PharmGKB summary: Peginterferon-α pathwayPharmacogenet Genomics. 2015 Sep; 25(9):465-74Shuldiner SR, Gong L, Muir AJ, Altman RB, Klein TE. PMID: 26111151 View all pathways on PharmGKB.

Subscribe to ClinPGx Blog

Don’t miss out on the latest issues. Sign up now to get access to the library of members-only issues.